Anti-Obesity Drugs Market by Type and Application - Global Industry Analysis & Forecast to 2027
Published On : January 2020 Pages : 154 Category: Pharma & Healthcare Report Code : HC018216
Anti-Obesity Drugs Market by Type (Diet Patch, Oral Medicine, Diet Tea) Application (Women, Men) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Anti-Obesity Drugs Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Anti-obesity drugs are pharmacological specialists that are useful to lose cholesterol and lessen the body weight. These medications for the most part show their activity by modifying the key working of the ordinary body by use of calories or by adjusting the craving.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Merck
- Pfizer
- Arena Pharmaceuticals
- Roche
- AstraZeneca
- GlaxoSmithKline
- Boehringer Ingelheim
- Eisai
- Novo Nordisk
- Norgine
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Anti-Obesity Drugs Market , By Type, Estimates and Forecast, 2017-2027 ($Million)
o Diet Patch
o Oral Medicine
o Diet Tea
· Anti-Obesity Drugs Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Women
o Men
· Anti-Obesity Drugs Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Merck
o Pfizer
o Arena Pharmaceuticals
o Roche
o AstraZeneca
o GlaxoSmithKline
o Boehringer Ingelheim
o Eisai
o Novo Nordisk
o Norgine
· Anti-Obesity Drugs Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Anti-Obesity Drugs Market , By Country
o U.S. Anti-Obesity Drugs Market
o Canada Anti-Obesity Drugs Market
o Mexico Anti-Obesity Drugs Market
o Europe
§ Europe Anti-Obesity Drugs Market , By Country
· Germany Anti-Obesity Drugs Market
o UK Anti-Obesity Drugs Market
o France Anti-Obesity Drugs Market
o Russia Anti-Obesity Drugs Market
o Italy Anti-Obesity Drugs Market
o Rest of Europe Anti-Obesity Drugs Market
o Asia-Pacific
§ Asia-Pacific Anti-Obesity Drugs Market , By Country
o China Anti-Obesity Drugs Market
o Japan Anti-Obesity Drugs Market
o South Korea Anti-Obesity Drugs Market
o India Anti-Obesity Drugs Market
o Southeast Asia Anti-Obesity Drugs Market
o Rest of Asia-Pacific Anti-Obesity Drugs Market
o South America
§ South America Anti-Obesity Drugs Market
o Brazil Anti-Obesity Drugs Market
o Argentina Anti-Obesity Drugs Market
o Columbia Anti-Obesity Drugs Market
o Rest of South America Anti-Obesity Drugs Market
o Middle East and Africa
§ Middle East and Africa Anti-Obesity Drugs Market
o Saudi Arabia Anti-Obesity Drugs Market
o UAE Anti-Obesity Drugs Market
o Egypt Anti-Obesity Drugs Market
o Nigeria Anti-Obesity Drugs Market
o South Africa Anti-Obesity Drugs Market
o Rest of MEA Anti-Obesity Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Anti-Obesity Drugs Market, By Type
5.1. Introduction
5.2. Global Anti-Obesity Drugs Revenue and Market Share by Type (2017-2027)
5.2.1. Global Anti-Obesity Drugs Revenue and Revenue Share by Type (2017-2027)
5.3. Diet Patch
5.3.1. Global Diet Patch Revenue and Growth Rate (2017-2027)
5.4. Oral Medicine
5.4.1. Global Oral Medicine Revenue and Growth Rate (2017-2027)
5.5. Diet Tea
5.5.1. Global Diet Tea Revenue and Growth Rate (2017-2027)
6. Anti-Obesity Drugs Market, By Application
6.1. Introduction
6.2. Global Anti-Obesity Drugs Revenue and Market Share by Application (2017-2027)
6.2.1. Global Anti-Obesity Drugs Revenue and Revenue Share by Application (2017-2027)
6.3. Women
6.3.1. Global Women Revenue and Growth Rate (2017-2027)
6.4. Men
6.4.1. Global Men Revenue and Growth Rate (2017-2027)
7. Anti-Obesity Drugs Market, By Region
7.1. Introduction
7.2. Global Anti-Obesity Drugs Revenue and Market Share by Regions
7.2.1. Global Anti-Obesity Drugs Revenue by Regions (2017-2027)
7.3. North America Anti-Obesity Drugs by Countries
7.3.1. North America Anti-Obesity Drugs Revenue and Growth Rate (2017-2027)
7.3.2. North America Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Anti-Obesity Drugs by Countries
7.4.1. Europe Anti-Obesity Drugs Revenue and Growth Rate (2017-2027)
7.4.2. Europe Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Anti-Obesity Drugs by Countries
7.5.1. Asia-Pacific Anti-Obesity Drugs Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Anti-Obesity Drugs by Countries
7.6.1. South America Anti-Obesity Drugs Revenue and Growth Rate (2017-2027)
7.6.2. South America Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Anti-Obesity Drugs by Countries
7.7.1. Middle East and Africa Anti-Obesity Drugs Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Merck
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Pfizer
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Arena Pharmaceuticals
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Roche
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. AstraZeneca
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. GlaxoSmithKline
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Boehringer Ingelheim
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Eisai
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Novo Nordisk
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Norgine
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Anti-Obesity Drugs Market Forecast (2017-2027)
9.1. Global Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Anti-Obesity Drugs Market Forecast by Regions (2017-2027)
9.2.1. North America Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.1.1. United States Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.1.2. Canada Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.1.3. Mexico Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.2. Europe Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.2.1. Germany Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.2.2. France Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.2.3. UK Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.2.4. Russia Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.2.5. Italy Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.3. Asia-Pacific Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.3.1. China Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.3.2. Japan Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.3.3. Korea Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.3.4. India Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.4. South America Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.4.1. Brazil Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.4.2. Argentina Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.4.3. Columbia Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.4.4. Rest of South America Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.5. Middle East and Africa Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.5.3. Egypt Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.5.4. Nigeria Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.5.5. South Africa Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.5.6. Turkey Anti-Obesity Drugs Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Anti-Obesity Drugs Market Forecast (2017-2027)
9.3. Anti-Obesity Drugs Market Forecast by Type (2017-2027)
9.3.1. Anti-Obesity Drugs Forecast by Type (2017-2027)
9.3.2. Anti-Obesity Drugs Market Share Forecast by Type (2017-2027)
9.4. Anti-Obesity Drugs Market Forecast by Application (2017-2027)
9.4.1. Anti-Obesity Drugs Forecast by Application (2017-2027)
9.4.2. Anti-Obesity Drugs Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Anti-Obesity Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Anti-Obesity Drugs Revenue and Revenue Share by Type (2017-2018)
Figure Global Diet Patch Revenue and Growth Rate (2017-2018)
Figure Global Oral Medicine Revenue and Growth Rate (2017-2018)
Figure Global Diet Tea Revenue and Growth Rate (2017-2018)
Table Global Anti-Obesity Drugs Revenue and Revenue Share by Application (2017-2018)
Figure Global Women Revenue and Growth Rate (2017-2018)
Figure Global Men Revenue and Growth Rate (2017-2018)
Table Global Anti-Obesity Drugs Revenue by Regions (2017-2018)
Figure North America Anti-Obesity Drugs Growth Rate (2017-2018)
Figure North America Anti-Obesity Drugs Revenue and Growth Rate (2017-2018)
Figure North America Anti-Obesity Drugs by Countries (2017-2018)
Figure North America Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Anti-Obesity Drugs Growth Rate (2017-2018)
Figure United States Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Canada Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Mexico Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Europe Anti-Obesity Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Anti-Obesity Drugs by Countries (2017-2018)
Figure Europe Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Germany Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Anti-Obesity Drugs Growth Rate (2017-2018)
Figure France Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Anti-Obesity Drugs Growth Rate (2017-2018)
Figure UK Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Russia Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Italy Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Rest of Europe Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Drugs by Countries (2017-2018)
Figure Asia-Pacific Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Anti-Obesity Drugs Growth Rate (2017-2018)
Figure China Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Japan Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Korea Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Anti-Obesity Drugs Growth Rate (2017-2018)
Figure India Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Southeast Asia Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Anti-Obesity Drugs Growth Rate (2017-2018)
Figure South America Anti-Obesity Drugs Revenue and Growth Rate (2017-2018)
Figure South America Anti-Obesity Drugs by Countries (2017-2018)
Figure South America Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Brazil Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Argentina Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Columbia Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Rest of South America Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Drugs by Countries (2017-2018)
Figure Middle East and Africa Anti-Obesity Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Anti-Obesity Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Egypt Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Nigeria Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Anti-Obesity Drugs Growth Rate (2017-2018)
Figure South Africa Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Turkey Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Anti-Obesity Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Merck Anti-Obesity Drugs Financial Overview
Table Pfizer Anti-Obesity Drugs Financial Overview
Table Arena Pharmaceuticals Anti-Obesity Drugs Financial Overview
Table Roche Anti-Obesity Drugs Financial Overview
Table AstraZeneca Anti-Obesity Drugs Financial Overview
Table GlaxoSmithKline Anti-Obesity Drugs Financial Overview
Table Boehringer Ingelheim Anti-Obesity Drugs Financial Overview
Table Eisai Anti-Obesity Drugs Financial Overview
Table Novo Nordisk Anti-Obesity Drugs Financial Overview
Table Norgine Anti-Obesity Drugs Financial Overview
Figure Global Anti-Obesity Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Anti-Obesity Drugs Market Forecast by Regions (2018-2025)
Figure North America Anti-Obesity Drugs Market Forecast (2018-2025)
Figure United States Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Canada Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Mexico Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Europe Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Germany Anti-Obesity Drugs Market Forecast (2018-2025)
Figure France Anti-Obesity Drugs Market Forecast (2018-2025)
Figure UK Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Russia Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Italy Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Rest of Europe Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Anti-Obesity Drugs Market Forecast (2018-2025)
Figure China Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Japan Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Korea Anti-Obesity Drugs Market Forecast (2018-2025)
Figure India Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Southeast Asia Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Anti-Obesity Drugs Market Forecast (2018-2025)
Figure South America Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Brazil Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Argentina Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Columbia Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Rest of South America Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Anti-Obesity Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Egypt Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Nigeria Anti-Obesity Drugs Market Forecast (2018-2025)
Figure South Africa Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Turkey Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Anti-Obesity Drugs Market Forecast (2018-2025)
Figure Global Anti-Obesity Drugs Forecast by Type (2018-2025)
Figure Global Anti-Obesity Drugs Market Share Forecast by Type (2018-2025)
Figure Global Anti-Obesity Drugs Forecast by Type (2018-2025)
Figure Global Anti-Obesity Drugs Forecast by Application (2018-2025)
Figure Global Anti-Obesity Drugs Market Share Forecast by Application (2018-2025)
Figure Global Anti-Obesity Drugs Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|